China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...
Drug
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...
CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...
InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...
Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...
Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...
Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73
China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...
Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors
China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...
Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...
Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...
HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...
Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...
Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy
Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...
Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio
China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...
Zai Lab’s Bemarituzumab Meets Phase III Endpoint in Gastric Cancer Trial
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that its Phase III FORTITUDE-101...
Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...
Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...
Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...